Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 381Breast Neoplasms 364Colorectal Neoplasms 238Stomach Neoplasms 218Carcinoma, Hepatocellular 155Lung Neoplasms 123Neoplasms 120Pancreatic Neoplasms 109Prostatic Neoplasms 100Neoplasm Metastasis 96Recurrence 95Rectal Neoplasms 95Ovarian Neoplasms 90Nasopharyngeal Carcinoma 88Esophageal Neoplasms 82Esophageal Squamous Cell Carcinoma 81Lymphoma, Large B-Cell, Diffuse 79Melanoma 75Small Cell Lung Carcinoma 71Uterine Cervical Neoplasms 70Lymphoma 70Leukemia, Myeloid, Acute 70Brain Neoplasms 69Sarcoma 68Head and Neck Neoplasms 68Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 65Carcinoma, Renal Cell 63Triple Negative Breast Neoplasms 61Lymphoma, Non-Hodgkin 53

Interventions

toripalimab 1liposomal doxorubicin 1disitamab vedotin 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Muscle Invasive Bladder Cancer × Clear all
NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown
6 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

NCT04101812 2019-09-26

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Tianjin Medical University Second Hospital

Phase 2 Unknown
60 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡